mortui personal page - To The Moon

mortui

No personal profile

7Follow

0Followers

0Topic

0Badge

2021-06-15

Wow

Sorry, the original content has been removed

2021-06-15

Nice spot

Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™

2021-06-19

$Senseonics(SENS)$pls bounce

2021-05-21

Nice grab today

2021-05-20

Nice rise

2021-05-12

$Sequential(SQBG)$please go up

Go to Tiger App to see more news

{"i18n":{"language":"en_US"},"userPageInfo":{"id":"3581118151417169","uuid":"3581118151417169","gmtCreate":1618324216214,"gmtModify":1618324216214,"name":"mortui","pinyin":"mortui","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":7,"tweetSize":6,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":6,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"44212b71d0be4ec88898348dbe882e03-3","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"President Tiger","description":"The transaction amount of the securities account reaches $1,000,000","bigImgUrl":"https://static.tigerbbs.com/fbeac6bb240db7da8b972e5183d050ba","smallImgUrl":"https://static.tigerbbs.com/436cdf80292b99f0a992e78750ac4e3a","grayImgUrl":"https://static.tigerbbs.com/506a259a7b456f037592c3b23c779599","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.29","exceedPercentage":"93.54%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-3","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Legendary Trader","description":"Total number of securities or futures transactions reached 300","bigImgUrl":"https://static.tigerbbs.com/656db16598a0b8f21429e10d6c1cb033","smallImgUrl":"https://static.tigerbbs.com/03f10910d4dd9234f9b5702a3342193a","grayImgUrl":"https://static.tigerbbs.com/0c767e35268feb729d50d3fa9a386c5a","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"93.27%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":4,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"baikeInfo":{},"tab":"hot","tweets":[{"id":165062220,"gmtCreate":1624081903560,"gmtModify":1703828494348,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>pls bounce","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>pls bounce","text":"$Senseonics(SENS)$pls bounce","images":[{"img":"https://static.tigerbbs.com/d2c198cf28559518483e1301d56e7ff9","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165062220","isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":187518460,"gmtCreate":1623758609350,"gmtModify":1703818325971,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice spot","listText":"Nice spot","text":"Nice spot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187518460","repostId":"1178091722","repostType":4,"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187535131,"gmtCreate":1623758352823,"gmtModify":1703818316316,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/187535131","repostId":"2143562407","repostType":4,"repost":{"id":"2143562407","pubTimestamp":1623757200,"share":"https://ttm.financial/m/news/2143562407?lang=&edition=fundamental","pubTime":"2021-06-15 19:40","market":"us","language":"en","title":"ContextLogic Inks Partnership Deal with PrestaShop; Shares Pop 12.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2143562407","media":"SmarterAnalyst","summary":"ContextLogic (WISH) has signed a two-year partnership deal with PrestaShop, a leading e-commerce pla","content":"<p>ContextLogic (<b>WISH</b>) has signed a two-year partnership deal with PrestaShop, a leading e-commerce platform. ContextLogic is an American online e-commerce platform that facilitates transactions between sellers and buyers.</p>\n<p>Following the deal announcement, shares of the company rose 12.7% to close at $11.27 on June 14.</p>\n<p>The partnership will enable merchants and brands on the PrestaShop platform to sell their products on the Wish marketplace. Moreover, PrestaShop merchants will be offered marketing and sales support, including special incentives.</p>\n<p>Wish will now be granted the official “Trusted Partner” status on PrestaShop. The deal will provide its customers with even more quality merchants and brands, which is expected to further boost online sales.</p>\n<p>ContextLogic’s Senior Business Development Manager Alan Small said, “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.” (See&nbsp;ContextLogic stock analysis&nbsp;on TipRanks)</p>\n<p>On May 13, Credit Suisse analyst&nbsp;Stephen Ju&nbsp;reiterated a Buy rating on the stock but decreased the price target to $24 from $31. This implies 113% upside potential to current levels.</p>\n<p>The analyst said that the better-than-expected revenue and adjusted EBITDA in Q1 were driven by higher AOVs and stronger logistics.</p>\n<p>The rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 4 Buys and 2 Holds. The&nbsp;WISH average analyst price target&nbsp;of $20.50 implies 81.9% upside potential from current levels. Shares have decreased 43.8% over the past six months.</p>\n<p><img src=\"https://static.tigerbbs.com/f6599a74f35e4651d39fd3a82e2fdbd2\" tg-width=\"1024\" tg-height=\"348\" referrerpolicy=\"no-referrer\"></p>\n<p><img src=\"https://static.tigerbbs.com/630a319313655e793da5a72016247792\" tg-width=\"663\" tg-height=\"440\" referrerpolicy=\"no-referrer\"></p>","source":"yahoofinance","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ContextLogic Inks Partnership Deal with PrestaShop; Shares Pop 12.7%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContextLogic Inks Partnership Deal with PrestaShop; Shares Pop 12.7%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-15 19:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/contextlogic-inks-partnership-deal-prestashop-105803315.html><strong>SmarterAnalyst</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>ContextLogic (WISH) has signed a two-year partnership deal with PrestaShop, a leading e-commerce platform. ContextLogic is an American online e-commerce platform that facilitates transactions between ...</p>\n\n<a href=\"https://finance.yahoo.com/news/contextlogic-inks-partnership-deal-prestashop-105803315.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://finance.yahoo.com/news/contextlogic-inks-partnership-deal-prestashop-105803315.html","is_english":true,"share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","article_id":"2143562407","content_text":"ContextLogic (WISH) has signed a two-year partnership deal with PrestaShop, a leading e-commerce platform. ContextLogic is an American online e-commerce platform that facilitates transactions between sellers and buyers.\nFollowing the deal announcement, shares of the company rose 12.7% to close at $11.27 on June 14.\nThe partnership will enable merchants and brands on the PrestaShop platform to sell their products on the Wish marketplace. Moreover, PrestaShop merchants will be offered marketing and sales support, including special incentives.\nWish will now be granted the official “Trusted Partner” status on PrestaShop. The deal will provide its customers with even more quality merchants and brands, which is expected to further boost online sales.\nContextLogic’s Senior Business Development Manager Alan Small said, “Wish serves millions of consumers around the world by providing high-quality products at affordable prices and a personalized, entertaining shopping experience. Partnering with PrestaShop will enable us to offer our consumers even more quality merchants and brands and to provide Prestashop merchants with a global platform to transact on.” (See ContextLogic stock analysis on TipRanks)\nOn May 13, Credit Suisse analyst Stephen Ju reiterated a Buy rating on the stock but decreased the price target to $24 from $31. This implies 113% upside potential to current levels.\nThe analyst said that the better-than-expected revenue and adjusted EBITDA in Q1 were driven by higher AOVs and stronger logistics.\nThe rest of the Street is cautiously optimistic about the stock with a Moderate Buy consensus rating based on 4 Buys and 2 Holds. The WISH average analyst price target of $20.50 implies 81.9% upside potential from current levels. Shares have decreased 43.8% over the past six months.","news_type":1},"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":139863453,"gmtCreate":1621606961372,"gmtModify":1704360493894,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice grab today","listText":"Nice grab today","text":"Nice grab today","images":[{"img":"https://static.tigerbbs.com/584d48f63a0b842403b427977ee583bc","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/139863453","isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":130325452,"gmtCreate":1621514585976,"gmtModify":1704358864993,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice rise","listText":"Nice rise","text":"Nice rise","images":[{"img":"https://static.tigerbbs.com/faf05775ba6f9a1a699dd5da3570f1e0","width":"1440","height":"4324"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130325452","isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":193399406,"gmtCreate":1620751218905,"gmtModify":1704347888209,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SQBG\">$Sequential(SQBG)$</a>please go up&nbsp;","listText":"<a href=\"https://laohu8.com/S/SQBG\">$Sequential(SQBG)$</a>please go up&nbsp;","text":"$Sequential(SQBG)$please go up","images":[{"img":"https://static.tigerbbs.com/316e9951940549c8bf09dc30ca5127ad","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193399406","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"hots":[{"id":187535131,"gmtCreate":1623758352823,"gmtModify":1703818316316,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Wow","listText":"Wow","text":"Wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/187535131","repostId":"2143562407","repostType":4,"isVote":1,"tweetType":1,"viewCount":308,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":187518460,"gmtCreate":1623758609350,"gmtModify":1703818325971,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice spot","listText":"Nice spot","text":"Nice spot","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/187518460","repostId":"1178091722","repostType":4,"repost":{"id":"1178091722","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1623757022,"share":"https://ttm.financial/m/news/1178091722?lang=&edition=fundamental","pubTime":"2021-06-15 19:37","market":"us","language":"en","title":"Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™","url":"https://stock-news.laohu8.com/highlight/detail?id=1178091722","media":"Tiger Newspress","summary":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and comm","content":"<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ocugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOcugen Secures Manufacturing Partnership for US Production of COVID-19 Vaccine Candidate, COVAXIN™\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2021-06-15 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p></p>\n<p><img src=\"https://static.tigerbbs.com/30195a620eedea62e516df9d39d4d93b\" tg-width=\"663\" tg-height=\"440\">Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.</p>\n<p>“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”</p>\n<p>“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.</p>\n<p>“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OCGN":"Ocugen"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1178091722","content_text":"Ocugen, Inc.(NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it has selected Jubilant HollisterStier of Spokane, Washington as its manufacturing partner forCOVAXIN™to prepare for potential commercial manufacturing of COVAXIN™ for the US and Canadian markets.\n“We are fully committed to bringing COVAXIN to the US and Canadian markets because we believe it has the potential to save lives by adding a weapon to the arsenal in the fight against emerging variants,” saidJ.P. Gabriel, Ocugen’s Senior Vice President, Manufacturing and Supply Chain. “Securing US-based manufacturing capability is a critical step as we prepare to submit our regulatory submissions to the FDA and Health Canada. Based on Bharat Biotech’s strong track record of developing and commercializing vaccines globally and Jubilant’s proven track record in manufacturing, we are well-prepared to transition US manufacturing of COVAXIN to our new partner.”\n“We are excited to expand our basket of vaccine products and meet the increasing demand from our customers for COVID-19 vaccines in the US,” said Amit Arora, President Jubilant HollisterStier.\n“We are pleased to partner with Ocugen and support the ongoing fight against COVID-19. With two facilities in North America working to manufacture multiple COVID-19 vaccines and therapies, we remain committed to supporting efforts to eradicate this global pandemic,” stated Pramod Yadav, CEO Jubilant Pharma Limited.","news_type":1},"isVote":1,"tweetType":1,"viewCount":355,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":165062220,"gmtCreate":1624081903560,"gmtModify":1703828494348,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>pls bounce","listText":"<a href=\"https://laohu8.com/S/SENS\">$Senseonics(SENS)$</a>pls bounce","text":"$Senseonics(SENS)$pls bounce","images":[{"img":"https://static.tigerbbs.com/d2c198cf28559518483e1301d56e7ff9","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/165062220","isVote":1,"tweetType":1,"viewCount":167,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":139863453,"gmtCreate":1621606961372,"gmtModify":1704360493894,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice grab today","listText":"Nice grab today","text":"Nice grab today","images":[{"img":"https://static.tigerbbs.com/584d48f63a0b842403b427977ee583bc","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/139863453","isVote":1,"tweetType":1,"viewCount":514,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":130325452,"gmtCreate":1621514585976,"gmtModify":1704358864993,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"Nice rise","listText":"Nice rise","text":"Nice rise","images":[{"img":"https://static.tigerbbs.com/faf05775ba6f9a1a699dd5da3570f1e0","width":"1440","height":"4324"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/130325452","isVote":1,"tweetType":1,"viewCount":341,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0},{"id":193399406,"gmtCreate":1620751218905,"gmtModify":1704347888209,"author":{"id":"3581118151417169","authorId":"3581118151417169","name":"mortui","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3581118151417169","authorIdStr":"3581118151417169"},"themes":[],"htmlText":"<a href=\"https://laohu8.com/S/SQBG\">$Sequential(SQBG)$</a>please go up&nbsp;","listText":"<a href=\"https://laohu8.com/S/SQBG\">$Sequential(SQBG)$</a>please go up&nbsp;","text":"$Sequential(SQBG)$please go up","images":[{"img":"https://static.tigerbbs.com/316e9951940549c8bf09dc30ca5127ad","width":"1440","height":"2560"}],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/193399406","isVote":1,"tweetType":1,"viewCount":460,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":1,"langContent":"EN","totalScore":0}],"lives":[]}